The Jackson Laboratory (JAX), a global leader in mammalian genetics and preclinical disease modeling, has been a driving force in supporting global drug discovery for 90 years. Our passion is empowering the development of novel therapeutics in our shared quest to advance human health. With the most comprehensive collection of over 11,000 mice, we are committed to providing critical tools to propel science, delineate the mechanisms underlying disease, and enable efficacious drug design. Leverage JAX
preclinical in vivo services offering robust scientific expertise, numerous in life and endpoint measurements, phenotyping capabilities, and flexible, customizable study designs for compound evaluation for many common models of neurological disorders, including Duchenne Muscular Dystrophy (DMD), Rett Syndrome, Friedreich’s Ataxia, Spinal Muscular Atrophy (SMA), Charcot-Marie Tooth (CMT), Epilepsy (EP), select models of Alzheimer’s disease (AD), and Amyotrophic Lateral Sclerosis (ALS).
The post Better Research Begins with an Experienced Solution Provider appeared first on GEN – Genetic Engineering and Biotechnology News.